Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
la Cour
Morten
M
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D016568:Drugs, Generic; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D000069579:Ranibizumab; D013810:Therapeutic Equivalency; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016568:Drugs, Generic; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab